‘Disappointed but not surprised': Measles cases explode in 19 states, new outbreak confirmed
(NEXSTAR) – Measles cases nationwide jumped dramatically this week, according to new numbers reported by the Centers for Disease Control and Prevention on Friday.
Nearly half of states are now reporting cases of the highly contagious virus, which can spread 'like a forest fire' through unvaccinated or undervaccinated communities.
More Local News
At least 483 cases are now confirmed in Alaska, California, Florida, Georgia, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New Mexico, New York, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, and Washington, according to the CDC.
At the beginning of the month, the number of confirmed cases was just 164.
Minnesota and Tennessee are the newest states to detect measles, and a new outbreak of at least 10 linked cases was confirmed in Ohio this week.
More: Latest News from Around the Tri-State
'Given the measles activity in Texas, New Mexico, and other states around the country, we're disappointed but not surprised we now have several cases in Ohio and known exposure in some counties,' said Ohio Department of Health Director Dr. Bruce Vanderhoff. 'This disease can be very serious, even deadly, but it is almost entirely avoidable by being properly vaccinated.'
Measles is considered one of the most contagious viruses in the world.
'On average, one infected person may infect about 15 other people,' Scott Weaver, a center of excellence director for the Global Virus Network, an international coalition, told the Associated Press. 'There's only a few viruses that even come close to that.'
The MMR (measles, mumps and rubella) vaccine is effective at preventing spread of the virus, but childhood vaccination rates have dropped as more families claim exemptions for religious or personal reasons. The first MMR shot is recommended for children between 12 and 15 months old and the second between 4 and 6 years old.
Measles isn't usually deadly, but it can have serious complications, especially for young children. Among kids with measles, about 1 in every 20 develops pneumonia, which can be fatal. Rare cases also suffer swelling of the brain called encephalitis — which can lead to convulsions, deafness or intellectual disability.
Fourteen percent of cases this year have required hospitalization, the CDC says. Most of those hospitalized have been children.
The Associated Press contributed to this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults
The US Food and Drug Administration (FDA) has expanded approval of Moderna's respiratory syncytial virus (RSV) vaccine to include younger adults at risk, though its still uncertain whether the shot will be recommended for broader use in the national immunisation schedule. Moderna's vaccine, known under the brand name mRESVIA, became the first non-Covid-19 messenger RNA-based (mRNA) vaccine to be approved in the US in May 2024. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older. The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV. This approval was supported by results from Moderna's Phase III study (NCT06067230), which demonstrated the vaccine's immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Infants and older adults remain the most vulnerable age groups to RSV, though over one-third of adults between 18 and 59 years of age have at least one underlying condition that puts them at increased risk of developing a severe form of the disease. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. Moderna said it plans to have mRESVIA available for both both younger adults and older adults in the US in time for the 2025-2026 respiratory virus season. This usually begins around November and peaks in the mid-Winter months. mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. The pharma company has been seeking outside investment to fund late-stage trials for further infectious disease vaccine candidates, amid a strategy to diversify its portfolio. Whilst the label expansion reflects an easing in regulatory tension surrounding mRNA vaccines under the Trump administration, FDA approval does not automatically mean shots enter national immunisation schedules. That is instead decided by the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). The CDC currently recommends the vaccine for adults aged 75 and older, as well as for adults aged 60 to 74 who are at increased risk of infection. In April, the CDC's ACIP recommended the use of approved RSV vaccines in at-risk adults aged 50 to 59. This week, US health secretary Robert F Kennedy (RFK) Jr axed the entire ACIP panel of experts, replacing members with vaccine sceptics and individuals with no prior public health strategy experience. The reshuffle has raised concerns about the future of the US immunisation schedule and the scope of vaccine recommendations. 'Investor focus will likely shift to the CDC's ACIP's next meeting, which is scheduled to proceed on June 25-27,' said William Blair analyst Miles Minter in a research note. 'This will be the first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view. Ultimately, we see the biggest headwind to the RSV vaccination market as restrictive ACIP recommendations that do not include re-dosing potential,' Minter added. The label expansion sees Moderna catch up with Pfizer, which already has an RSV vaccine approved for adults aged 18 years and over. Like mRESVIA, Pfizer's Abrysvo has the requirement of increased disease risk for those between 18 and 59, whilst anyone above the age of 60 is eligible for the jab. Pfizer still has a market advantage, however, with Abrysvo the only vaccine product approved for infants. It also gained FDA approval a year before mRESVIA, giving it first to market advantage. GSK also has an FDA-approved vaccine in the form of Arexvy, though its label only covers those at risk in individuals aged between 50 through 59 years, along with the standard indication of ages 60 and over. "Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
(Reuters) -Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs the U.S. Centers for Disease Control and Prevention's recommendation before it is made available for the age group. It is already approved for use in adults aged 60 or older. The biotech's stock extended its decline into the second session, following the appointment of the new panel late Wednesday. Some of the new appointees have openly expressed anti-vaccine views, including against the mRNA vaccine technology on which Moderna's shots are based. Earlier this week, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the panel, known as the Advisory Committee on Immunization Practices (ACIP), saying it would "re-establish public confidence in vaccine science" - a move health experts warn could undermine public confidence in available vaccines. The ACIP advises the CDC on who should get the shots after they are approved by the U.S. Food and Drug Administration. The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view," said William Blair analyst Myles Minter. U.S.-listed shares of GSK and Pfizer fell marginally and those of smaller Novavax were down 1.7% at $7.03 in premarket trade. The CDC currently recommends Moderna's vaccine for adults aged 75 and older, as well as for at-risk adults aged 60 to 74. In April, the ACIP recommended the use of approved RSV vaccines in at-risk adults aged 50 to 59. However, the CDC is yet to sign off on the recommendation.


Fast Company
42 minutes ago
- Fast Company
‘Nimbus' new Covid variant: Tracking symptoms like ‘razor blade throat' as NB.1.8.1 spreads in U.S.
It's easy to forget, but Covid-19 is still commonplace around the world, and the virus is still mutating, unleashing new variants across the globe. The latest variant, nicknamed 'Nimbus,' that health authorities are keeping an eye on is now spreading rapidly in the United States. And it has a painful new symptom you should be aware of. Here's what to know about the Covid-19 Nimbus variant. What is Nimbus? Nimbus is one of the latest variants of Covid-19 that health authorities are keeping an eye on. Its lineage designation is NB.1.8.1 and is a subvariant of omicron. According to the World Health Organization (WHO), Nimbus was first detected in January 2025. But it has since spread and is likely to become the leading variant of Covid-19 that is circulating around the world. Indeed, the U.S. Centers for Disease Control and Prevention (CDC) shows that Nimbus's spread is making rapid gains in America. For the two-week period ending May 24, Nimbus accounted for about 15% of all reported Covid-19 cases in the country. But by the two-week period ending June 7, Nimbus accounted for 37% of cases. In the same period, the currently dominant LP.8.1 accounted for 38% of Covid-19 cases in America. 'Razor blade throat' and other symptoms Nimbus has several common symptoms, many of which are shared by other Covid-19 variants. According to Today, these symptoms include: Cough Runny nose or congestion Shortness of breath Fever or chills Headache Body aches Fatigue New loss of sense of smell or taste Yet people infected with Nimbus have also reported another symptom—a sore throat. But many who have experienced this symptom say the throat soreness is more intense than what one usually experiences. Some have described the Nimbus sore throat symptom as feeling like you have razor blades in your throat. Because of this, the symptom has been nicknamed 'razor blade throat.' However, Dr. Peter Chin-Hong, an infectious disease specialist at the University of California, San Francisco, told the San Francisco Chronicle that despite the nickname, a sore throat is actually a common symptom of Covid-19. 'Sore throat is a common symptom of COVID and not novel at all, and not associated with any one variant, including NB.1.8.1,' Chin-Hong said. 'There has been a range of intensity of sore throat with COVID symptoms all along, including very severe pain.' Which states have Nimbus spread to? CDC reporting of Covid-19's spread isn't as robust as it once was, and the agency has not reported exactly which states Nimbus has spread to as of this time. However, as noted by Today, data from the Global Initiative on Sharing All Influenza Data (GISAID) shows that Nimbus is in at least 14 states. Those states include: Arizona California Colorado New Jersey New York Hawaii Illinois Maryland Massachusetts Ohio Rhode Island Vermont Virginia Washington How can I protect myself against Nimbus? The best way to protect yourself from Covid-19 is by taking a three-pronged approach, according to the CDC. That includes: Staying up to date with your Covid-19 vaccinations. Practicing good hygiene. Taking steps for cleaner air, including letting fresh air circulate through your house. While any new Covid-19 variant no doubt causes anxiety and uncertainty in many, there is good news at the moment: According to the WHO, current data does not indicate that the NB.1.8.1 'Nimbus' variant leads to more severe illness than other variants currently making the rounds. However, it's worth pointing out that Covid-19 can still be deadly. According to WHO data, in the last 28 days, 862 people in the United States have died after contracting the disease. Since the start of the pandemic, 1.2 million people in the United States have died due to Covid-19, and 7.1 million people have succumbed to the disease worldwide.